Ramucirumab
| CAS No. | 947687-13-0 | Cat. No. | BCP29228 |
| Name | Ramucirumab | ||
| Synonyms | Cyramza; IMC-1121B; LY3009806; IMC-1121B; KDR; | ||
| Formula | M. Wt | ||
| Description | Recombinant monoclonal antibody to VEGF Receptor 2. Ramucirumab (IMC-1121B) is a fully human monoclonal antibody (IgG1) for the treatment of solid tumors. It is directed against the vascular endothelial growth factor receptor 2 (VEGFR2). By binding to VEGFR2 it works as a receptor antagonist blocking the binding of vascular endothelial growth factor (VEGF) to VEGFR2. VEGFR2 is known to mediate the majority of the downstream effects of VEGF in angiogenesis. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | VEGFR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.